Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials

2753 results

Sort By:

A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL

Study ID: NCT06979076
Start Date: 2026-07
End Date: 2028-12
Study Type

Interventional

Study Phase

Phase2

No. of Participants

12

Intervention / Treatment

MS-553, DS1

MS-553, DS2

Sponsor

MingSight Pharmaceuticals, Inc

Source: clinicaltrials.gov

Share:
Add to list

Intraarticular Gold Microparticles for Knee Osteoarthritis

Study ID: NCT07202390
Start Date: 2026-02-01
End Date: 2029-02-01
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

240

Intervention / Treatment

20 mg metallic gold microparticles (72.000 particles, 20-40 µm) will be injected into the knee joint using 2 mL hyaluronic acid.

Intervention

Sponsor

Northern Orthopaedic Division, Denmark

Source: clinicaltrials.gov

Share:
Add to list

High Cardiovascular Risk Intervention With Cardio-Oncology Consultation for Prostate Cancer Following Androgen Receptor Pathway Inhibitor (ARPI) Therapy (Heart-Safe)

Study ID: NCT07223385
Start Date: 2025-12
End Date: 2029-12
Study Type

Interventional

Study Phase

Phase2

No. of Participants

80

Intervention / Treatment

Cardio-Oncology Referral

Notification to PCP/General Cardiologist

Sponsor

Cedars-Sinai Medical Center

Source: clinicaltrials.gov

Share:
Add to list

Intraoperative Placement of Vancomycin-impregnated Calcium Sulfate Beads Conjugated With Analgesics to Improve Spine Surgery Outcomes

Study ID: NCT07201987
Start Date: 2026-01
End Date: 2027-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

100

Intervention / Treatment

Vancomycin (local, via calcium sulfate beads)

Morphine (local, via calcium sulfate beads)

Bupivacaine (local, via calcium sulfate beads)

Sponsor

Ganesh m. Shankar

Source: clinicaltrials.gov

Share:
Add to list

EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer

Study ID: NCT05467748
Start Date: 2025-11-17
End Date: 2029-11-16
Study Type

Interventional

Study Phase

Phase2

No. of Participants

66

Intervention / Treatment

Tulmimetostat

Sponsor

VA Office of Research and Development

Source: clinicaltrials.gov

Share:
Add to list

HIV Testing in Community Health Center Dental Clinics

Study ID: NCT07089849
Start Date: 2026-09
End Date: 2028-03
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

6715

Intervention / Treatment

Rapid HIV testing

Referral for HIV testing

Sponsor

Boston University

Source: clinicaltrials.gov

Share:
Add to list

The Use of Urinary Dickkopf 3 (u DKK3) as a New Biomarker Which Can Identify Patients at High Risk of Renal Allograft Dysfunction, Earlier That the Current Established Tests.

Study ID: NCT07176806
Start Date: 2026-01
End Date: 2027-01
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

258

Intervention / Treatment
Sponsor

Guy's and St Thomas' NHS Foundation Trust

Source: clinicaltrials.gov

Share:
Add to list

Remote Fentanyl Test Strip Distribution and Education to Prevent Drug Overdose

Study ID: NCT07128485
Start Date: 2026-09
End Date: 2027-09
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

100

Intervention / Treatment

Fentanyl test strips

Fentanyl test strip education

Sponsor

University of Alabama at Birmingham

Source: clinicaltrials.gov

Share:
Add to list

A Study to Learn How Well Mirena Works as Compared to Oral Progestin in Nonatypical Endometrial Hyperplasia in Women Who Have Started Their Periods

Study ID: NCT06904274
Start Date: 2025-12-01
End Date: 2027-01-20
Study Type

Interventional

Study Phase

Phase3

No. of Participants

300

Intervention / Treatment

BAY865028

Medroxyprogesterone acetate

Sponsor

Bayer

Source: clinicaltrials.gov

Share:
Add to list

Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford

Study ID: NCT05416554
Start Date: 2025-12
End Date: 2027-12
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

20

Intervention / Treatment

Neuropsychological testing

Sponsor

Stanford University

Source: clinicaltrials.gov

Share:
Add to list